Bacterial conjunctivitis is one of the most commonly occurring eye infections, in which conjunctiva is inflamed by bacteria such as Moraxella lacunata, Staphylococcus aureus and others. There has been a rising prevalence of bacterial infection in the infants and geriatrics as they fall in the highly susceptible category. This increasing occurrence of the infection demands efficient medications, which is leading to the rising demand of the medications across the globe. However, the increasing volume of generic drugs in the market, patent expirations of various major drugs and rising drug-resistant bacterial strains are some of the key challenges, which may hinder market growth for these drugs over the forecast period.
The introduction of various patient-awareness programs and co-pay assistance facility to patients by vendors is also anticipated to have a positive impact on the bacterial conjunctivitis market growth of these drugs in the near future. Rising occurrence of assistance programs by drug suppliers is making patients inclined toward purchasing branded therapies. The increasing consumer-awareness about bacterial conjunctivitis has resulted in an increased prevention and control of the infection.
The global bacterial conjunctivitis drugs market has been segmented based on drug class into fluoroquinolones (ciprofloxacin, ofloxacin, levofloxacin, moxifloxacin, gatifloxacin, besifloxacin), aminoglycosides (tobramycin and gentamycin), macrolides (erythromycin, azithromycin) and others. The fluoroquinolones are the leading drug segment and are projected to witness a considerable growth in the near future as it is widely prescribed by medical practitioners due to its higher efficiency against various bacterial strains across the globe.
North America dominates the bacterial conjunctivitis drugs market and is anticipated to grow at a moderate rate over the forecast period on account of rising prevalence of ophthalmic bacterial infections coupled with growing demand for antibacterial drugs in the region. According to a study conducted by the American Medical Association in 2013, bacterial conjunctivitis accounts for more than 50% of the conjunctivitis cases in America. These statistics show that the U.S. is witnessing high occurrence of this infection, therefore leading to high demand for these drugs in the region. The Asia Pacific market is also expected to grow at a moderate rate in the near future due to increasing patient awareness and high disposable income for their wellbeing.
The key players include Allergan plc, Akorn, Inc., Bayer AG, Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Perrigo Company plc, Pfizer, Inc., Santen Pharmaceutical Co., Ltd. and Valeant Pharmaceuticals International, Inc. The future global market of bacterial conjunctivitis drugs would be dependent on the commercialization of drugs due to loss of patent exclusivity.
DecisionDatabases.com is a global business research reports provider, enriching decision makers and strategists with qualitative statistics. DecisionDatabases.com is proficient in providing syndicated research reports, customized research reports, company profiles and industry databases across multiple domains.
Our expert research analysts have been trained to map the client’s research requirements to the correct research resource leading to a distinctive edge over its competitors. We provide intellectual, precise and meaningful data at a lightning speed.
www.decisiondatabases.com is a online aggregator of market and research database which includes databases, reports and profiles. We have started this portal with a aim to become one stop shop provider for marketing and research data requirements for various sector and country databases.